Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis
Status:
Completed
Trial end date:
2020-11-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if a sequential combination therapy of natalizumab
and alemtuzumab induces peripheral tolerance and reduces the annualized relapse rate (ARR) in
patients with relapsing-remitting multiple sclerosis (RRMS).